AstraZeneca gets US FDA nod for FARXIGA to treat chronic kidney disease
In DAPA-CKD Phase III trial, FARXIGA demonstrated reduction in the risk of the composite of worsening of renal function, end-stage…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Farxiga
T2D market will grow from a total of $48.1bn sales in 2019 to $91.9 bn in 2029
T2D market growth factors are increasing diagnosed prevalence of disease and the emergence of novel pipeline agents
US FDA approves AstraZeneca’s diabetes drug for treating heart failure risk
The approval by the US Food and Drug Administration is based on results from the DECLARE-TIMI 58 clinical trial
FDA gives fast track status to AstraZeneca’s diabetes drug Farxiga
In July, the US regulators had declined to approve Farxiga as a supplement to insulin in adults with type-1 diabetes where insulin…
AstraZeneca’s Farxiga meets main goal of heart failure study
Farxiga belongs to a class of medicines called SGLT2 inhibitors, which control blood sugar levels by causing the kidneys to expel…